

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/091379 A2

- (51) International Patent Classification⁷: **A61B**
- (21) International Application Number:
PCT/US2004/009114
- (22) International Filing Date: 26 March 2004 (26.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/459,286 31 March 2003 (31.03.2003) US
- (71) Applicant (for all designated States except US): **UNIVERSITY OF FLORIDA** [US/US]; P.O. Box 115500, Gainesville, FL 32611-5500 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SHAW, Gerry** [GB/US]; 6401 SW 111th Avenue, Gainesville, FL 32608 (US). **PIKE, Brian, R.** [US/US]; 7213 Titonka Way, Derwood, MD 20855 (US). **TULL, Sonal, S.** [—/US]; 3944 SW 95th Drive, Gainesville, FL 32608 (US).
- (74) Agent: **STANLEY, Kim, A.**; Akerman Senterfitt, 222 Lakeview Avenue, Suite 400, West Palm Beach, FL 33402-3183 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/091379 A2

(54) Title: ASSESSING NEURONAL DAMAGE FROM BLOOD SAMPLES

(57) Abstract: Neuronal damage is detected by providing a biological sample derived from the subject, detecting in the sample the presence of a neurofilament subunits or their breakdown products, and correlating the presence and level of the neurofilament subunits and their breakdown products detected with the degree of neuronal injury.

ASSESSING NEURONAL DAMAGE FROM BLOOD SAMPLES

CROSS REFERENCE TO RELATED APPLICATION

This application claims priority from U.S. provisional patent application serial
5 number 60/459,286, filed March 31, 2003.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with United States government support under grant
number DAMD17-01-1-0765 awarded by the United States Army, and grant number
AA012151-02 awarded by the National Institutes of Health. The United States
10 government may have certain rights in the invention.

FIELD OF THE INVENTION

The invention relates generally to the fields of biology and medicine. More
particularly, the invention relates to detecting damage to neuronal cells by analyzing a
biological sample for neurofilament (NF)-derived proteins and peptides (NFDP)
15 released from damaged neurons.

BACKGROUND

In recent years much interest has been focused on the detection of specific
marker proteins in blood to rapidly diagnose various kinds of damage and disease
states. Such so-called biomarkers, when studied in detail, have the potential to
20 provide quick and simple diagnosis of a variety of damage and disease states. For
example, it has been known for many years that the presence of tissue polypeptide
antigen (TPA) in human serum is a useful biomarker for several forms of carcinoma,
and the level of TPA expression is negatively correlated with cancer prognosis. TPA
was initially identified by raising antisera against the insoluble residues of extracted
25 human tumors, and the assumption from the early work was that the components of
TPA would be tumor-specific proteins (Bjorklund, B, Antibiot. Chemother. 22:16-31,
1978). However later studies indicated that TPA was actually a complex of partially
degraded keratins 8, 18 and 19, which are abundant components of the cytoskeleton
of normal differentiating epithelia cells as well as of carcinoma cells (Weber et al.,
30 Embo. J. 3:2707-2714, 1984). Apparently the rapidly dividing carcinoma cells
release some of their cytoplasmic components into the serum where they are
somewhat resistant to serum proteases and so can be detected by appropriate
immunological tests. Individuals with carcinomas of the appropriate type therefore
have much larger amounts of these circulating protein fragments than do normal

individuals. Since the level of TPA expression in serum accurately reflects the carcinoma cell load, TPA determinations have both diagnostic and prognostic value. Another example of this kind of approach is the monitoring of myocardial infarction, in which levels of cardiac creatine kinase and cardiac troponin I are measured. The serum content of these proteins, released from damaged cardiac cells, provides medically useful information bearing on the size of the infarction which has prognostic value. These kinds of finding and many others establish the principle that normal proteins of cells may be expressed at much higher levels in serum in certain specific kinds of damage and disease state, and their immunological detection may be of diagnostic and prognostic use.

Although diseases associated with neuronal injury are a major health concern worldwide, a truly reliable and convenient specific biomarker of neuronal injury has not been found, even though such a marker has great scientific and potential clinical usefulness (Ingebrigtsen and Romner, *J. Trauma* 52:798-808, 2002). A few potential markers of brain injury have been described but all have disadvantages. For example, previous studies have proposed that S100- β , neuron specific enolase (NSE) (Persson et al., *Stroke* 18:911-918, 1987) and more recently spectrin breakdown products (SBPs, Pike et al., *J Cereb Blood Flow Metab* 24:98-106, 2004) in biological samples may be useful for measuring brain injury. However neither S100- β nor SBPs, are specific for neuronal or even nervous system damage. Neuron-specific enolase looks more promising, since it is expressed in large amounts only in neurons, but has not been widely used perhaps because NSE is a relatively unstable protein. Microtubule associate protein (MAP) tau has also been proposed as a biomarker of neuronal injury (Zemlan et al., *J Neurochem* 72:741-750, 1999). However it is not a particularly abundant protein and is also expressed in non-neuronal cells (e.g., reactive astrocytic glial cells (Togo and Dickson, *Acta Neuropathol.* 104:398-402, 2002)). A need therefore exists for a rapid and reliable diagnostic assay that can be used to conveniently assess neuronal damage. Such an assay would be useful to assess neuronal injury in experimental animals and to monitor the effects of drugs which may be neuroprotective in these animals. Such an assay would be particularly useful if the relevant molecule could be detected in blood rather than cerebro spinal fluid (CSF), since obtaining blood is not only routine in research and medical contexts, but is also much easier, less invasive and less potentially dangerous than obtaining CSF.

The potential biomarker would be particularly useful if it could be detected in blood within a few hours of trauma, since this would allow it to be used in the emergency room to monitor human accident victims with potential neuronal injury in the spinal cord or brain. It is difficult to determine how much neuronal injury has occurred in accident victims using current X-ray, CAT scan and MRI technology. The detection and quantitation of a biomarker of neuronal injury may therefore have considerable diagnostic and prognostic value in humans.

SUMMARY

The invention relates to the discovery that injury to central nervous system (CNS) tissue such as spinal cord or brain in an experimental animal leads to the leakage of proteins originating from NF that can be detected in biological fluids such as blood and CSF of the animal. The presence of these NF-derived proteins can be detected using assays utilizing antibodies that specifically bind particular NFDPs. Because NF expression is absolutely restricted to neurons, measurement of NFDPs provides a way to specifically and unambiguously detect neuron damage.

NF are composed predominantly of three subunit proteins, namely NF-L, NF-M, NF-H, with smaller amounts of two further proteins, α -internexin and peripherin (Shaw, 1998 Neurofilaments. New York: Springer). When neurons are damaged NF subunits, normally found in stable 10nm diameter filaments, are broken down to soluble components under the influence of various endogenous enzymes, such as the calpains, cathepsins, caspases and others. These enzymes produce a family of soluble NFDPs. NFDPs are soluble and diffusible proteins derived from assembled NF, and may be either fully intact NF subunit proteins or proteolytically processed fragments of NF subunits.

The NF subunit most resistant to proteases is NF-H and this, coupled with some unusual protein chemical and immunological properties of this molecule suggested that this was the most likely to be easily detected in blood, CSF and other bodily fluids following neuronal injury. Based on the foregoing a prototype enzyme-linked immunosorbent assay (ELISA) capture assay was developed. Current version of this assay can reliably detect NF-H in small 50 μ l volumes in quantities as low as 50pg (equivalent to 1ng/ml or 1 μ g/L, see figure 1). The prototype assay was used to examine NF-H immunoreactivity in control rat blood and in the blood of rats which had been subjected to various different experimental neuronal injuries. No NF-H

immunoreactivity could be detected in control blood, but up to 60 μ g/L NF-H immunoreactivity was detected in the blood of rats given experimental spinal cord injuries. Rats given experimental traumatic brain injuries also showed reproducible but rather lower NF-H signals in blood. Various other neuronal injury paradigms have revealed reproducible NF-H signals in the blood. In summary, a whole series of experiments show that NF-H can be detected by an appropriate antibody based assay in blood of animals which have received experimental neuronal injuries. The NF-H signal could be readily detected not only in blood, but also in sera following clotting of blood and also in plasma, showing that the signal was present in the soluble fraction of blood and not associated with red blood cells or other cellular components.

Specifically, rats were given spinal cord hemisection at the thoracic levels T11, T12 levels. This system is used to model knife and bullet wounds to the CNS. Samples of blood taken from the site of the cut injury showed very high levels of NF-H expression (>80 μ g/L), showing that NF-H is released in easily detectable amounts immediately following this kind of neuronal injury. Samples of blood taken from the tail at 2, 8, 16 and 24 hours, all revealed small but reproducible NF-H signals, with stronger signals at later time points. These findings establish the principle that NF-H is found in blood in the hours following neuronal injury in readily measurable amounts. Interestingly the levels of NF-H in this series of experiments plateau at about 24 hours, and then go to even higher levels peaking between 3 and 5 days following injury, returning to control levels by about 9 days post injury. This second peak of immunoreactivity is thought to correspond to the secondary death of neurons, and this assay is thought to provide a unique method of measuring this phenomena. This experiment has been performed on a series of animals, all of which produced very similar time courses and degrees of NF-H signal, suggesting that the response of the animal to the injury and the NF-H detection are both reliable and reproducible. Another series of experiments show that experimental spinal cord contusion injuries in rats produce a quantitatively and qualitatively similar NF-H response. Contusion was produced using a standardized weight drop apparatus, and this model system is used to model human crush and impact lesions of the spinal cord. Finally studies of rats subjected to experimental traumatic brain injury, also using a weight drop apparatus, show a measurable but smaller NF-H signal in blood compared to those

subjected to spinal cord injury. In summary, blood NF-H levels are able to reliably detect a variety of different kinds of central nervous system neuronal injury.

The ELISA assay described herein is rapid, currently performed in slightly more than three hours, and non-invasive, requiring only a drop of blood. The assay works with fresh blood, serum obtained following clotting at room temperature or plasma obtained by centrifugation. For uniformity, the assay was standardized on plasma which was obtained from fresh blood by centrifugation at 14,000g for 10 minutes at room temperature. 10 μ l samples from experimental rats was routinely used though greater sensitivity could no doubt be obtained with larger samples. The NF-H signal is quite stable and can be detected without apparent diminution following several cycles of freezing and thawing of blood, serum or plasma, or following several hours at room temperature. This means that the assay is likely to be robust in practice. The assay can be used in animal studies aimed at quantitating neuronal injury and assessing the effectiveness of drugs designed to combat neuronal death. A robust and rapid assay of neuronal injury also has great potential for use on human spinal cord and brain injury patients in the emergency room.

Accordingly, the invention features a method of detecting a neuronal injury in a subject. This method includes the steps of: (a) providing a biological sample derived from the subject (e.g., blood, serum, plasma, CSF or other fluids); (b) detecting the presence of or quantifying in the sample at least one NFDP; and (c) correlating the presence or quantity of the NFDP in the sample with the neuronal injury. Step (b) can include contacting the sample with at least one antibody that specifically binds at least one NFDP. It can also involve performing an immunoassay selected from the group consisting of immunoblotting, ELISA, radioimmunoassay, surface plasmon resonance, immunodiffusion or fluorescence energy transfer. The NFDP could also be detected by means of a specific non-antibody based ligand such as an engineered derivative of a PDZ, 14-3-3 or other binding domain, engineered endogenous NFDP binding proteins, or a ligand specifically designed to bind the NFDP in question.

The invention also features a kit for detecting and quantitating neuronal injury in a subject. This kit includes a solid or nanoparticle substrate to which has been bound an appropriate capture antibody that binds strongly and specifically to a specific NFDP, and a second antibody for detecting binding of the appropriate NFDP

to this capture antibody. The kit can include other appropriate reagents to visualize and quantitate the amount of captured NFDP. It can also include instructions for using the kit to detect and quantitate NF-H levels, reflective of neuronal injury, in an appropriate fluid sample. Detection reagents may include appropriate chromogenic enzymes, radioactive probes, fluorescent probes, metal nanoparticles or plastic nanoparticles. Recent advances using nucleic acid based signal amplification may also be employed (e.g. Nam et al., Science 301:1884-1886, 2003). The NFDP can be NF-H, but may also include reagents to detect NFDP containing part or all of the NF-M, NF-L, α -internexin or peripherin molecules. In the kit, detecting binding of at least one antibody to the NFDP is correlated with the degree of neuronal injury.

As used herein, "bind," "binds," or "interacts with" means that one molecule recognizes and adheres to a particular second molecule in a sample, but does not substantially recognize or adhere to other structurally unrelated molecules in the sample. Generally, a first molecule that "specifically binds" a second molecule has a binding affinity greater than 10^5 to 10^6 moles/liter for that second molecule.

The term "blood," as used herein, means the blood derivatives plasma and serum.

By reference to an "antibody that specifically binds" to another molecule is meant an antibody that binds the other molecule, and displays no substantial binding to other naturally occurring proteins other than those sharing the same antigenic determinants as the other molecule. The term "antibody" includes polyclonal and monoclonal antibodies as well as antibody fragments or portions of immunoglobulin molecules that can specifically bind the same antigen as the intact antibody molecule.

The term "subject," as used herein, means a human or non-human animal, including but not limited to mammals such as a dog, cat, horse, cow, pig, rabbit, guinea pig, sheep, goat, primate, rat, and mouse. Since the immunogenic regions of NF-H are well conserved across higher vertebrate species, the current NF-H assay is expected to work on avian and reptilian subjects also. By similar reasoning, assays based on the detection of other NFDPs are also likely to work on all higher vertebrate species.

Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those

described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including
5 definitions, will control. In addition, the particular embodiments discussed below are illustrative only and not intended to be limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph showing the results of ELISA with variable amounts of pure NF-H, illustrating the sensitivity of the prototype assay. The ordinate plots the serial
10 dilution series of a typical ELISA plate, such that the first well is undiluted (100%, to the right), the second is diluted 50%, the third 25% and so on. A straight line indicates a linear and hence quantifiable response. Amounts as low as 50pg of NF-H can be readily and reproducibly detected in small (50 μ l) samples.

FIG. 2 is a graph showing results from ELISAs performed to determine NF-H
15 concentration in a set of 10 μ l plasma samples taken at the indicated time from a single animal which had been given an experimental spinal cord hemisection. Note the marked increase in NF-H detectable in the first few hours after injury, and the even greater peak seen after 3-4 days.

FIG. 3 is a graph showing NF-H immunoreactivity in rat serum following
20 experimental spinal cord contusion injury. 50 μ l samples of blood were allowed to clot and serum was taken for the ELISA assay. Levels of NF-H increase up to 3-5 days, then decline back to baseline by 7 days.

DETAILED DESCRIPTION

The invention relates to compositions and methods for detecting NFDPs in a
25 biological sample such as CSF or blood to assess neuronal injury. The below described preferred embodiments illustrate adaptations of these compositions and methods. Nonetheless, from the description of these embodiments, other aspects of the invention can be made and/or practiced based on the description provided below.

Biological Methods

30 Methods involving conventional biological techniques are described herein. Such techniques are generally known in the art and are described in detail in methodology treatises such as *Molecular Cloning: A Laboratory Manual*, 3rd ed., vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor,

N.Y., 2001; and Current Protocols in Molecular Biology, ed. Ausubel et al., Greene Publishing and Wiley-Interscience, New York, 1992 (with periodic updates). Immunological methods (e.g., preparation of antigen-specific antibodies, immunoprecipitation, and immunoblotting) are described, e.g., in Current Protocols in Immunology, ed. Coligan et al., John Wiley & Sons, New York, 1991; and Methods of Immunological Analysis, ed. Masseyeff et al., John Wiley & Sons, New York, 1992.

NFDPs

NFDPs are generated by the enzymatic digestion of NFs by activated proteases. NFs are the major structural components of neurons and belong to the 10nm diameter or intermediate filament protein family. NFs are composed of the major subunits NF-L, NF-M and NF-H, with certain types of neuron containing smaller amounts of two further subunits, peripherin and α -internexin. The other members of the 10nm diameter or intermediate filament protein family include the keratins found in epithelial cells, glial fibrillary acidic protein (GFAP) characteristic of astrocytic cells, desmin found in muscle and endothelial cells, vimentin found in many cell types and several less well known proteins. This family of proteins has several interesting properties. First, they are expressed in well defined, specific cell subtype expression patterns. This means, for example, that antibodies to NFs can be used to unequivocally identify cells as being neuronal in origin, and GFAP antibodies are used as the gold standard for the identification of astrocytes. Second, the different intermediate filament proteins and their subunits are extremely abundant components of many cells, and in many large neurons NF subunits may represent several percent of the total amount of protein. Third, NF subunits and the subunits of other 10nm filament are long lived and stable components of the cell which therefore must be rather resistant to normal cellular proteolytic mechanisms. These properties make the 10nm or intermediate filament proteins in general and the neurofilament molecules in particular excellent targets for the development of diagnostic kits aimed at analyzing cell type specific damage.

The large neurons of the mature nervous system are particularly rich in NF-L, NF-M and NF-H. The three polypeptides are each complex multidomain proteins which in the cases of NF-M and NF-H are unusually heavily phosphorylated. When the nervous system is damaged, neuronal cells die either apoptotically or necrotically

and are expected to release their contents into the surrounding tissues, the blood and the cerebrospinal fluid. This material is expected to be partially proteolysed, since both apoptosis and necrosis result in the activation of a series of proteolytic enzymes. However NF-H is both highly immunogenic and resistant to proteases, so that intact
5 NF-H or fragments derived from NF-H are likely to be detectable in bodily fluids following release from damaged neurons. As shown above, NF-H can be detected in blood in large amounts at the site of a lesion, in blood as little as two hours after this injury, and in blood over the several days following neuronal injury.

Because NFs are found only in neuronal cells, this approach has a
10 considerable advantage over other methods. Previous workers have used S100- β and spectrin breakdown products which can be detected in blood and in CSF as markers of brain injury. However, both of these proteins are found not only in neurons but also glia, endothelia, and many other types of cells and are not specific to cells within the CNS. Therefore, a test based on NF detection provides much more refined
15 information and offers greater scientific and clinical value since it reflects solely damage to neurons. As noted above MAP-tau and neuron specific enolase are other potential markers of neuronal injury which also have specific disadvantages. A NF detection system is also likely to provide greater sensitivity since NF are thought to be the most abundant neuronal-specific component, and are particularly heavily
20 expressed in large species such as notably human.

Detecting Neuronal Injuries

The invention provides a method for detecting a neuronal injury in a subject. The method includes the steps of: (a) providing a biological sample derived from the subject, e.g. blood or CSF; (b) detecting the presence in the sample of NFDPs
25 generated from intact NFs; (c) comparing the quantity of NFDPs in the sample to the quantity of NFDPs in a sample from a normal (i.e., non-injured) control subject; and (d) correlating the amounts of the NFDPs in the sample of step (a) with the severity of the injury.

The step of providing a biological sample derived from the subject can be
30 performed by conventional medical techniques. A biological sample can be from any site in the body of the subject. While NF-H is expected to accumulate in CSF following neuronal injury, and could be assayed there, a great advantage of the present method is that an adequate signal can be detected in blood. Blood is much

more easily obtained than CSF, and is routinely taken from experimental animals and from human patients in the emergency room. No extra specific steps are therefore needed beyond the availability of an appropriate kit to detect NF-H.

Suitable subjects for use in the invention can be any animal species expressing
5 NF which can be detected with our assay system. The subject can therefore be any mammal such as dog, cat, horse, cow, pig, rabbit, guinea pig, sheep, goat, primate, rat, or mouse. It is expected that this assay will work at least on avian and reptilian species, if not also amphibian and fish. A preferred subject for the methods of the invention is a human being. Particularly preferred are subjects suspected of having or
10 at risk for developing traumatic or non-traumatic neuronal injuries, such as victims of neuronal injury caused by traumatic insults (e.g., gunshot wounds, automobile accidents, sports accidents), ischemic events (e.g., stroke, cerebral hemorrhage, cardiac arrest) and neurodegenerative disorders (e.g., Alzheimer's and Parkinson's diseases).

15 The step of detecting the presence of NFDPs in a sample can be performed in a variety of different ways. Numerous suitable techniques are known for analyzing the presence of protein. For example, proteins and specific breakdown products of the same proteins can be detected using immunological techniques, e.g., using antibodies that specifically bind the protein and/or its breakdown products (e.g., NFs,
20 their subunits and breakdown products produced by specific proteases) in immunoassays such as immunoblotting (e.g., Western blotting), ELISA, radioimmunoassay (RIA), immunofluorescence or immunohistochemical staining and analysis, and similar techniques. Suitable methods for detecting NFDPs are described below; nonetheless, other suitable methods might also be employed.

25 Any antibody that binds to NFDPs is suitable for use in the invention. In a preferred embodiment, a single antibody can be used to concurrently or independently detect a specific NFDPs. In one aspect of the invention, immunoblots of protein samples can be probed with an anti-NFDP antibody that detects only a specific NFDP (e.g., NF-H).

30 **Kits**

The invention includes a kit for assaying the levels of NFDPs in a biological sample such as blood or CSF (e.g., to detect a neuronal injury in a subject). The kit includes a solid substrate, at least one capture antibody that binds specifically to a defined NFDP, another antibody specific for the relevant NFDP used to detect the

NFDP bound to the capture antibody, and instructions for using the kit to detect neuronal injury in a subject. The kit typically includes an NFDP-specific polyclonal, monoclonal or recombinant antibodies immobilized on ELISA plates, glass slides or other suitable substrates. The immobilized antibody is incubated with the biological sample allowing binding of the specific NFDP (e.g., NF-H) that may be contained in the sample. The binding of the specific product is determined by a detection antibody specific for the particular NFDP. The presence of the detection antibody is visualized and quantified by detection agents such as enzyme-linked antibodies reactive with the detection antibody. The presence of the enzyme linked antibody is detected using chromogenic substrate molecules appropriate for the enzyme. Quantitation of the signal can then be performed by optical density measurements at the wavelength optimum for the particular chromagen. More complex approaches utilize surface plasmon resonance, fluorescence resonance energy transfer or other techniques which involve the use of specialized equipment to assay binding may have advantages in terms of quantifying binding and for high-throughput applications.

In developing the invention, a series of specific polyclonal antibodies to NF subunits were made in rabbit and chicken, and certain monoclonal antibodies were made in mouse. In the prototype ELISA assay described here we used a very high titre chicken polyclonal antibody to NF-H in the capture mode. This was affinity purified on pure NF-H, and coated onto ELISA plates using standard methods. The detection antibody was a rabbit polyclonal antibody which was also affinity purified in the same way. The combination of two polyclonal antibodies made in two different species gives unusual sensitivity to this assay. Other antibodies that specifically bind additional particular NFDPs will be assessed for utility in future. Such kits would include reagents to detect NF-M, NF-L, α -internexin and peripherin. Kits within the invention could also include antibody probes to glial fibrillary acidic protein (GFAP) so that glial damage could also be assessed. More advanced and automated kits use protein microarrays based on the same antibody reagents. Such arrays could be used in both basic research and clinical (e.g., emergency room) applications. Additionally, a colorimetric filter-based assay using specific immobilized antibodies is within the invention.

EXAMPLES

Example 1 – Neurofilament Subunit NF-H As A Robust Serum

Biomarker Of Neuronal Injury

Materials and Methods

Development of NF-H specific antibodies: Since bovine tissues can be obtained relatively easily and since the bovine NF-H molecule is immunologically and protein chemically similar to that of humans and other species, we used bovine NF-H to prepare antibodies reactive with NF-H. Bovine spinal cord tissue was obtained from a local slaughter house, transported on ice, desheathed of meninges and stored at -70°C. Neurofilament rich gels were prepared essentially as described by Delacourte et al. (Delacourte et al., *Biochem J* 191:543-546, 1980). Briefly, ~250g of the bovine spinal cord material was thawed out and homogenized in a blade type homogenizer in MES Buffer (0.1M MES, 1mM EGTA, 0.5mM MgCl₂ pH=6.5, plus 0.2mM PMSF). The homogenate was filtered through cheese cloth and centrifuged at 14,000 rpm/29,000g for one hour at 4°C. The supernatant was then centrifuged at 28,000 rpm/78,000g for 30 minute at 4°C. Glycerol was added to give a final concentration of 20% and the material was incubated for 20 minutes at 37°C. The supernatant was centrifuged at 45,000 rpm/235,000g for 30 minutes at 20°C. Typically about 3g of clear yellowish pellets were collected per preparation. These pellets typically contain about 90% NF-L, NF-M and NF-H, with smaller amounts of GFAP and fodrin/spectrin. This material was dissolved in 6M urea in 10mM phosphate buffer, 1mM EDTA, 0.1% β-mercaptoethanol, pH = 7.5, and applied to a DEAE cellulose column equilibrated in the same buffer. Proteins were eluted using a NaCl gradient from 0M to 0.25M in the same buffer. A single clean NF-H protein band eluted at about 0.05M NaCl, and this material was concentrated to about 1mg/ml and dialyzed against PBS. 250µg of purified NF-H were mixed 1:1 with Freund's complete adjuvant and injected into mice, rabbits and chickens, and then 3 weeks later animals were boosted with 200µg mixed 1:1 with Friends incomplete adjuvant.

Following two further boosts, two rabbits were exsanguinated and sera collected for affinity purification. For chickens, eggs were taken and IgY-enriched preparations produced by delipidation in organic solvents followed by ammonium sulphate precipitation. The mice were sacrificed and their spleen cells fused with PAI myeloma were processed for hybridoma production using standard methods. The hybridoma were grown in 6 by 24 well dishes, and were screened by ELISA on the immunogen. The NP1 hybridoma was selected for subcloning as it reacted extremely strongly with NF-H in ELISA and also stained neurons in unfixed and

paraformaldehyde fixed histological sections. The chicken polyclonal IgY preparation is designated CPCA-NF-H, the rabbit polyclonal serum is designated RPCA-NF-H and the mouse monoclonal is designated MCA-NP1. All three are now obtainable commercially from EnCor Biotechnology Inc. (Alachua, FL). Prior to use
5 in these assays, both the rabbit sera and IgY preps were affinity-purified on purified NF-H coupled to cyanogen bromide activated Sepharose 4B (Sigma). The mouse monoclonal was affinity purified on a Hi-Trap Protein G column (Amersham) following the manufacturers instructions. Eluted antibodies were dialyzed against PBS prior to use in ELISA assays.

10 Prototype ELISA Assay: To perform ELISA assays, Immulon 4HBX plates, which are standard 96 well format ELISA coated to improve protein binding, were used. Affinity purified chicken antibody to NF-H was quantified by UV absorbance and 100µl amounts were applied at 0.7 µg/ml in 50mM sodium bicarbonate buffer at pH = 9.5. Plates were incubated at 4°C overnight and then the next day blocked for at
15 least 1 hour with 150µl of 5% Carnation non-fat milk in Tris buffered saline (TBS). Then the plates were washed in TBS plus 0.1% Tween 20 (TBS/Tween) using a Biorad ELISA plate washer set at 300µl volume, 4 seconds soak time per cycle, 5 cycles. Plates could then be stored in a humid box at 4°C in 100µl/well TBS/Tween containing 1mM sodium azide, or could be used for assays immediately. To perform
20 an assay 50µl of ELISA incubation buffer (2% Carnation non fat milk, in TBS/Tween) was applied to each well. Up to 50µl of blood or other protein sample was then applied to the A row of each plate, and this material was serially diluted down the dish, allowing the analysis of up to 12 samples per plate.

After 1 hour incubation with shaking at room temperature, the plate was
25 washed several times in TBS/Tween using a Biorad ELISA plate washer as before. Affinity purified rabbit detection antibody to NF-H at about 50µg/ml concentration was added to 10 mls of ELISA incubation buffer per ELISA plate, and 100µl of this solution was applied to each well. After incubation for 1 hour at room temperature with shaking, the plate was again washed in TBS/Tween on the ELISA washer, each
30 well was incubated with 1:2,000 goat anti-rabbit alkaline phosphatase conjugate (Sigma) in ELISA incubation buffer. After another hour incubation at room temperature with shaking, the plates were washed for a final time on the ELISA plate washer as before and developed with 100µl/well of 0.1 M Glycine, 1mM Mg, 1mM

Zn at pH = 10.4 containing 1mg/ml p-Nitrophenyl Phosphate (Sigma). After 20 minutes to 1 hour development, the reaction was stopped with 50 μ l/well of 2M NaOH, and results were quantitated on a Tecan Spectrafluor plus ELISA plate reader using 405nm absorbance.

5 Animal Experiments: Female Long-Evans rats weighing 230-300 grams were obtained from Harlan (Indianapolis, IN). All surgical procedures were performed under sterile conditions with supplemental heat. Intraperitoneal administration of Nembutal (sodium pentobarbital) at 50-60 mg/kg was used to induce anesthesia. Following either partial T11, T10 laminectomy with the dura mater intact, injury was
10 produced by scalpel hemisection was performed at the T12, T11 spinal level. A small sample of blood was taken from the cut region. The incisions were closed in layers, and animals were allowed to recover in a heated incubator with food and water ad libitum. Bladders were expressed and fluids were administered when required. In the case of the animals treated with the lesion, blood samples were taken by tail bleeding
15 at 2hrs, 8hrs, 16hrs, 24hrs, 2days and every following day out to 11 days. A typical result is shown in Figure 2. ELISA consistently shows a strong peak of NF-H in serum at 3-4 days post-injury. Significantly however, NF-H can be robustly detected at as little as 8 hours post injury, and a weak but reproducible signal was seen at 2 hours postinjury. ELISA assays showed a consistent and marked expression of NF-H
20 in the blood taken from the injury site, actually much higher than the levels seen in sera at later time points. These experiments show that NF-H is immediately released into the blood following nerve injury and can furthermore be consistently and reproducibly detected in the hours and days following experimental nervous system injury.

25 It is particularly significant that NF-H is detectable at the site of injury and in the few hours following injury. This allows an assay based on these findings to detect neuronal injury in human patients in the emergency room. Detection of serious neuronal injury by other means, such as MRI, X-Rays, CAT scanning etc, is problematic; An assay based on these findings could rapidly detect neuronal injury in
30 an unconscious patient and the level of NF-H detected is very likely to have prognosticative value.

In another set of experiments spinal cord injury was produced using a standardized New York impactor device with a 10g weight falling 25mm. Sham injury animals received a laminectomy and were placed in the injury apparatus but

were not injured. The experimentally treated animals were sacrificed at 24, hours, 48 hours, 72 hours, 5 days, 7 days and 6 weeks after injury. Blood was collected and allowed to clot for 1-2 hours at room temperature, and then stored frozen. As shown in Figure 3 strong signals were obtained from serum samples of animals which had spinal cord contusion injuries. The amount of NF-H detected was significant after 24 hours and increased over 48 and 72 hours. At 5 days the level of NF-H was somewhat lower and by 7 days was almost back to background levels. The signals were surprisingly strong and by comparison with standards, the NF-H level in the experimental animals sera was calculated to be in the range from 26µg/L in the 24 hour animals to as much as 66µg/L in the 72 hour post injury animals. Untreated animals were those which did not have mechanical injuries and were typically being sacrificed at the end of experiments performed for reasons irrelevant to these studies, and revealed no detectable NF-H signal. Further controls were sham treated animals, which were anesthetized and had their spinal cords exposed as did the experimental group, but were not subjected to the weight drop paradigm. None of these animals showed any significant NF-H immunoreactivity with the current assay.

Because it would be advantageous to know exactly what form of NF-H is being detected in this assay, the sera from a rat given a spinal cord injury 3 Days previously and which had shown a strong signal in the ELISA assay was subjected to preliminary fractionation. Fractions of serum protein were obtained by ammonium sulphate precipitation. Fractions were assayed using ELISA, and a weak signal was obtained in the first fraction and a much stronger one in the second fraction, while in subsequent fractions the signal was essentially at background levels. The second fraction was therefore subjected to gel filtration on a Superose column (Pharmacia), and fractions were again screened using the ELISA assay. The NF-H immunoreactivity eluted very early in the profile indicative of a molecular weight in the range of 0.5 million Daltons. This indicates that the NF-H signal is at least multimeric and perhaps part of a complex of proteins.

Example 2 – Variations of the Assay

In addition to the assay described above, there are many possible variations that may be useful in detecting NFDPs in the sera of an animal. For example, the use of avidin-biotin conjugate-based methods may greatly increase the sensitivity of ELISA assays. As another example, modifications such as using higher antibody concentrations and incubations at 37°C rather than room temperature may improve the

assay. The development of assays involving rapid colorimetric or other methods which would allow the determination of NF-H serum level in minutes is also envisioned. Such an approach could potentially be useful in the diagnosis of human patients. A kit which detects NF-H in sera using, for example, a simple diffusion and antibody capture procedure run in a filter, as has been developed for other kinds of biomarker found in sera and other fluids, may be particularly useful. This kit could be used to quantitate the degree of neuronal damage in a variety of situations apart from the examples illustrated here. An assay which detects such markers is useful experimentally in animal studies and is expected to be diagnostically useful in humans. In particular, the degree of neuronal injury in spinal cord injury and traumatic brain injury patients is difficult to determine using MRI or by other current imaging methods. An assay based on detection of a readily detectable neuronal protein such as this one could rapidly assess the degree of neuronal damage in such accident victims. Using methods and compositions of the invention, it is expected that the level of NF-H expression can be correlated with a specific degree of neuronal injury and a specific prognosis.

Other Embodiments

While the above specification contains many specifics, these should not be construed as limitations on the scope of the invention, but rather as examples of preferred embodiments thereof. Many other variations are possible. Accordingly, the scope of the invention should be determined not by the embodiments illustrated, but by the appended claims and their legal equivalents.

What is claimed is:

25

1. A method of detecting a neuronal injury in a subject, the method comprising the steps of:

- (a) providing a biological sample derived from the subject;
- (b) detecting the presence or amount of at least one neurofilament derived protein or peptide (NFDP) in the sample;
- (c) correlating the presence or amount of the NFDP in the sample with the neuronal injury.

2. The method of claim 1, wherein the step (b) of detecting the presence or amount of at least one NFDP in the sample comprises contacting the sample with at least one antibody that specifically binds the at least one NFDP.

3. The method of claim 1, wherein the step (b) of detecting the presence or amount of at least one NFDP in the sample comprises performing an immunoassay selected from the group consisting of immunoblotting, ELISA, radioimmunoassay, immunodiffusion and immunoprecipitation.

4. The method of claim 1 wherein the biological sample is a fluid selected from the group consisting of blood, serum, plasma, and CSF.

5. The method of claim 1, wherein the step (b) of detecting the presence of or quantifying in the sample at least one NFDP comprises contacting the sample with an antibody that specifically binds NF-H.

6. The method of claim 5, wherein the step (b) of detecting the presence or amount of at least one NFDP in the sample comprises performing an ELISA.

7. A kit for detecting a neuronal injury in a subject, the kit comprising:

- (a) a solid substrate;
- (b) at least one antibody that binds specifically to an NFDP;
- (c) an agent for detecting binding of the at least one antibody to the NFDP; and
- (d) instructions for using the kit to detect neuronal injury in a subject.

8. The kit of claim 7, wherein the NFDP is NF-H.

9. The kit of claim 7, wherein the agent for detecting binding of the at least one antibody to the NFDP comprises a chromogenic substrate molecule.

5

10. The kit of claim 7, wherein detecting binding of the at least one antibody to the NFDP is correlated with neuronal injury.

10




FIG. 1




FIG. 2




FIG. 3

专利名称(译)	评估血液样本的神经元损伤		
公开(公告)号	EP1613204A2	公开(公告)日	2006-01-11
申请号	EP2004758954	申请日	2004-03-26
[标]申请(专利权)人(译)	佛罗里达大学		
申请(专利权)人(译)	佛罗里达大学		
当前申请(专利权)人(译)	佛罗里达州研究基金会, Inc.的大学.		
[标]发明人	SHAW GERRY PIKE BRIAN R TULI SONAL S		
发明人	SHAW, GERRY PIKE, BRIAN, R. TULI, SONAL, S.		
IPC分类号	A61B1/00 G01N33/68 A61B C07K16/18 G01N33/48 G01N33/53 G01N33/537 G01N33/543 G01N33/567		
CPC分类号	G01N33/6896 C07K16/18 G01N2333/47 G01N2800/28		
代理机构(译)	FERRECCIO, RINALDO		
优先权	60/459286 2003-03-31 US		
其他公开文献	EP1613204A4 EP1613204B1		
外部链接	Espacenet		

摘要(译)

通过提供源自受试者的生物样品, 在样品中检测神经丝亚单位或其分解产物的存在, 并将神经丝亚单位的存在和水平与其检测到的分解产物与神经元损伤程度相关联来检测神经元损伤。。